Back to search results

Triamcinolone and Vitamin D for Psoriasis

This study is looking at how well a combination of triamcinolone (a cream for skin conditions) and Vitamin D3 (a daily supplement) works to treat mild to severe plaque psoriasis. Researchers want to see if these two treatments together are more effective than triamcinolone alone. You might be able to join if you are 18 or older and have plaque psoriasis affecting at least 2% of your body. The study will measure improvements in your psoriasis symptoms, like how much skin is affected and how severe it is, over 28 weeks. The current status of this study is unclear, and it plans to enroll 24 participants.

Study design
This interventional study will first treat all 24 participants with triamcinolone cream for 4 weeks. Then, participants will be randomly assigned to receive either Vitamin D3 or a placebo (an inactive substance) for 12 weeks, followed by an open-label period where all participants receive Vitamin D3 for another 12 weeks.
What's involved
You would use triamcinolone cream daily for 4 weeks, then either Vitamin D3 or a placebo daily for 12 weeks, and finally Vitamin D3 daily for another 12 weeks. The total study duration is 28 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your psoriasis symptoms will be assessed at Week 28 to measure improvements from the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04036188

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
Wright State University
~24 participants
Updated 2026-02-19 on ClinicalTrials.gov
What's tested:TriamcinoloneVitamin D3Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improvement in Psoriasis Area and Severity Score (PASI) from baseline
Measured over Week 28
+2 more outcomes measured

Conditions

Plaque Psoriasis
Vitamin D3

Explore related trials

Chronic small plaque psoriasis

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Jeffrey B Travers, MD, PhD · PRINCIPAL_INVESTIGATOR · Wright State University

Who to contact

Manager, Clinical Research Operations
[email protected]
937-245-7500
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 and older
Mild to severe plaque psoriasis (2% or greater Body Surface Area; Psoriasis Area and Severity Score of 2 or greater; Investigator Grade Assessment of mild-severe)

Exclusion

Currently taking medication that alters the normal ion balance of low-dose in blood.
No calcium supplements 1 month prior to baseline (not including multivitamins).
Unstable or uncontrolled illness, including but not limited to cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disease at screening.
Abnormal laboratory values at screening, that in the opinion of the investigator, would potentially affect patient safety or data integrity.
Not on systemic non-biologic therapy (including, but not limited to, oral psoralen plus ultraviolet A \[photochemotherapy (PUVA)\] light therapy; cyclosporine; corticosteroids; methotrexate; oral retinoids; apremilast; tofacitinib; mycophenolate mofetil; thioguanine; hydroxyurea; sirolimus; tacrolimus; azathioprine; leflunomide; fumaric acid derivatives; or 1, 25 dihydroxy vitamin D3 and analogues) within 28 days prior to baseline.
No phototherapy (including either oral and topical PUVA light therapy, ultraviolet B, excimer laser, or self-treatment with tanning beds or therapeutic sunbathing) within 28 days prior to baseline.
No topical treatment (including, but not limited to, corticosteroids \[upper mid strength or lower potency topical steroids are permitted on the intertriginous areas and face\], crisaborole, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, pimecrolimus, tacrolimus, emollients and other nonprescription topical products containing urea, \>3% salicylic acid, alpha- or beta-hydroxyl acids, or medicated shampoos \[for example those that contain \>3% salicylic acid, corticosteroids, coal tar, or vitamin D3 analogues\]) within 14 days prior to baseline.
No biologic agents within 8 weeks or three half-lives, whichever is greater prior to baseline.
History of renal impairment.
History of renal stones.
History of parathyroid abnormalities
Osteoporosis
History of severe arthritis
Ongoing use of tanning bed or other UV device or excessive sunlight
Unable to understand/complete informed consent.

What this trial measures

  • Improvement in Psoriasis Area and Severity Score (PASI) from baselineWeek 28

    Subjects achieving a 50% improvement from baseline (PASI 50)

  • Improvement in Investigator Grade Assessment (IGA) from baselineWeek 28

    Subjects achieving a 1 point reduction from baseline

  • Improvement in Body Surface Area (BSA) from baselineWeek 28

    Subjects achieving a 50% reduction from baseline